ed by overexpression of the aurora and Ipl1 like midbody associated protein mitotic kinase in human cancer cells. Cancer Res 1998,58:4811�?. 44. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer EPO906 Microtubule Formation inhibitor Inst 1999,91:1160�?. 45. Meraldi P, Honda R, Nigg EA. Aurora A overexpression reveals tetraploidization as a major route to centrosome amplification in p53 / cells. Embo J 2002,21:483�?2. 46. Ota T, Suto S, Katayama H, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM 1/Aurora B overexpression contributes to chromosome number instability. Cancer Res 2002,62:5168�?7. 47. Kanda A, Kawai H, Suto S, et al. Aurora B/AIM 1 kinase activity is involved in Ras mediated cell transformation. Oncogene 2005,24:7266�?2. 48.
Pollard JR, Mortimore M. Discovery and development of aurora kinase inhibitors as anticancer agents. J Med Chem 2009,52:2629�?1. 49. Ditchfield C, Johnson VL, Elesclomol Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp E to kinetochores. J Cell Biol 2003,161:267�?0. 50. Harrington EA, Bebbington D, Moore J, et al. VX 680, a potent and selective small molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004,10:262�?. 51. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active smallmolecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007,104:4106�?1. 52. Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
Clin Cancer Res 2007,13:3682�?. 53. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007,110:2034�?0. 54. Schellens JH, Boss D, Witteveen PO, et al. Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152. Journal of Clinical Oncology 2006,24 abstr 3008. 55. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX 680 induces endoreduplication and apoptosis preferentially in cells with compromised p53 dependent postmitotic checkpoint function. Cancer Res 2006,66:7668�?7. Dar et al.
Page 13 Mol Cancer Ther. Author manuscript, available in PMC 2011 February 2. NIH PA Author Manuscript NIH PA Author Manuscript NIH PA Author Manuscript 56. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug resistant BCR ABL mutations with altered oncogenic potency. J Clin Invest 2007,117:2562�?. 57. Huang XF, Luo SK, Xu J, et al. Aurora kinase inhibitory VX 680 increases Bax/Bcl 2 ratio and induces apoptosis in Aurora A high acute myeloid leukemia. Blood 2008,111:2854�?5. 58. Hoar K, Chakravarty A, Rabino C, et al. MLN8054, a small molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007,27:4513�?5. 59. Zhang M, Huck J, Hyer M, Ecsedy J, Manfredi M.
Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B cell non Hodgkin,s lymphoma models. Journal of Clinical Oncology 2009,27 abstr 8553. 60. Soncini C, Carpinelli P, Gianellini L, et al. PHA 680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res 2006,12:4080�?. 61. Tao Y, Zhang P, Frascogna V, et al. Enhancement of radiation response by inhibition of Aurora A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53 deficient cancer cells. Br J Cancer 2007,97:1664�?2. 62.